SNPMiner Trials (Home Page)
Report for Clinical Trial NCT01101438
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
This study is looking at whether Metformin, an agent that is commonly used to treat diabetes,
can decrease or affect the ability of breast cancer cells to grow and whether Metformin will
work with other therapies to keep cancer from recurring. Health Canada has not approved the
sale or use of Metformin to treat breast cancer, although they have approved its use in this
clinical trial. Although Metformin is approved by the FDA for the treatment of diabetes, its
use in breast cancer is considered investigational.
Name: metformin hydrochloride
Description: Given orallyType: Drug
Arm I
Name: placebo
Description: Given orallyType: Other
Arm II
Primary Outcomes
Measure: Invasive disease-free survival in hormone receptor (ER and PgR) negative and positive (ER and/or PgR) sub-groups
Time: 10 years
Secondary Outcomes
Measure: Overall survival
Time: 10 years
Measure: Distant relapse-free survival
Time: 10 years
Measure: Breast cancer-free interval
Time: 10 years
Measure: Long-term clinical and laboratory safety
Time: 10 years
Measure: Relevant medical endpoints (new diabetes, new cardiovascular hospitalizations)
Time: 10 years
Measure: Health-related quality of life, physical activity, and diet
Time: 10 years
Measure: Change in body mass index
Time: 10 years
Measure: Correlative science outcomes
Time: 10 years
Purpose: Treatment
Allocation: Randomized
Parallel Assignment
There is one SNP
SNPs
1 P13K
- Concurrent or planned participation in randomized trials of weight loss or exercise
interventions or trials targeting insulin, IGF-1 or their receptors, or involving P13K
inhibitors (at the time of randomization)*. --- P13K ---
HPO Nodes
HPO:Breast carcinoma
Genes 95
TP53 PPM1D CTNNB1 TP53 COL14A1 AKT1 AKT1 OPCML MDM2 BRCA1 SLC22A18 POLE BRCA2 BRCA1 SDHC NTHL1 PTEN XRCC3 MSH6 IDH1 RAD51C RAD51C CASP8 RB1CC1 PIK3CA PALLD KRAS PIK3CA CHEK2 BRIP1 MRE11 NTHL1 ATM TP53 RAD51D STK11 PRKN ESR1 PIK3CA KLLN MSH2 SDHD KRAS SEC23B HMMR PTEN POLD1 PIK3CA IDH2 BRCA1 PALB2 BRIP1 TP53 RAD51 RNF43 BARD1 BARD1 AAGAB AKT1 SMAD4 RAD50 STK11 CHEK2 RAD54L NBN CDKN2A SEC23B CDH1 WRN NQO2 PALB2 ATR PALB2 TWIST1 SDHB MSH2 BRCA2 BRCA1 RAD51 CHEK2 MLH1 BRCA1 FGFR2 TP53 PHB BRCA2 CDH1 PTEN BRCA2 CHEK2 CDKN2A APC MLH1 AKT1 APC hr>Neoplasm of the breast
Genes 123
PPM1D CTNNB1 PTEN MGMT AKT1 BRCA1 SLC22A18 BRCA1 SDHC NTHL1 XRCC3 APC IDH1 LMNA RAD51C CDKN2B PIK3CA PALLD CHEK2 NTHL1 ATM RAD51D ESR1 GNAS APC PIK3CA RASGRP1 SDHD PRKCD KRAS BAP1 IDH2 PALB2 FAS RAD51 RNF43 PRLR AKT1 CHEK2 CDKN2A CDH1 CDK4 RELA BRCA2 BRCA1 TERF2IP CHEK2 MLH1 BRCA1 PRKAR1A POT1 BRCA2 CDH1 TERT APC MLH1 AKT1 TP53 CASP10 TP53 COL14A1 AKT1 OPCML MDM2 POLE BRCA2 PTEN MSH6 RAD51C CASP8 RB1CC1 KRAS ACD PIK3CA BRIP1 MRE11 TP53 STK11 PRKN KLLN MSH2 SEC23B HMMR PTEN POLD1 PIK3CA BRCA1 MITF FAS BRIP1 TP53 BARD1 BARD1 AAGAB SMAD4 RAD50 STK11 RAD54L NBN C11ORF95 SEC23B WRN PTEN NQO2 PTEN PALB2 ATR PALB2 CDKN2A TWIST1 SDHB MSH2 MC1R FASLG RAD51 FGFR2 TP53 PHB PTEN BRCA2 CHEK2 CDKN2A APC hr>